Croda International Earnings Call: Recovery With Risks

Croda International ((GB:CRDA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Croda International’s latest earnings call painted a cautiously upbeat picture for investors. Management highlighted solid organic growth, rising adjusted profitability and improving free cash flow, all underpinned by early wins from a multi‑year transformation program. However, sizeable non‑cash impairments, volatility in Pharma and Industrial Specialties, and ongoing restructuring mean the recovery still carries execution risk.

Broad-Based Top-Line Growth Across Core Divisions

Sales rose 7% in constant currency to £1.7bn for FY2025, with Q4 up 5% on the same basis. Growth was well spread, as Consumer Care and Life Sciences each delivered 8% full-year growth, and both divisions sustained that momentum into Q4 with 9% and 8% gains respectively.

Patented Ingredients and Customer Metrics Strengthen

Patented ingredient sales increased 9%, underscoring Croda’s shift toward higher-value, defensible technologies. Management also pointed to an 11‑point improvement in Net Promoter Score, signalling stronger customer trust, better service and deeper collaboration with key accounts.

Adjusted Profitability Moves Higher Despite Headwinds

Adjusted operating profit climbed 8% to £295m, while adjusted profit before tax also grew 8% to £276m. EBITDA increased 5% to £397m, reflecting early benefits from cost savings and mix improvement, even as FX and inflation created a drag on reported margins.

Free Cash Flow Rebounds and Balance Sheet Tightens

Free cash flow reached £162m in FY2025, helped by lower capital expenditure and tighter working capital in the second half. Net debt edged down to £524m and leverage improved to 1.3x EBITDA from 1.5x, giving Croda more flexibility to fund growth and the transformation agenda.

CapEx Discipline Supports Cash and Returns

Capital expenditure was cut from £138m to £108m, beating prior guidance of £135m. Management now targets CapEx at roughly 6% of sales going forward, signalling a more disciplined approach to investment while still supporting key innovation and capacity priorities.

Transformation Program Delivering Early Savings

The transformation program delivered £28m of recurring savings in 2025, with further efficiencies to come. By FY2028, Croda is targeting £100m of annualized savings and a £50m working capital reduction, with roughly £75m of additional benefits expected to underpin margin recovery.

Ambitious 2028 Financial Targets Laid Out

Management set a three-year framework aiming for group organic sales growth of 3–6% per year, with Life Sciences at 4–7% and Consumer Care at 3–6%. The company is also targeting an adjusted operating margin above 20% by FY2028, free cash flow conversion above 12% and a return on invested capital above 10%.

Repositioning Toward High-Growth Niches and Regions

Croda’s portfolio now generates 89% of sales from consumer, pharma and agricultural markets, up from 73% in 2019. Nearly half of sales now come from outside Europe and North America, while faster‑growing niches such as fragrances and flavors, plant stem cells and biologics are outpacing their underlying markets.

Segment Standouts in Fragrances, Crop and Beauty

Fragrances & Flavors posted 15% growth in FY2025, reflecting strong demand in specialty scent and taste applications. Crop Protection grew 14% for the year, with Q4 up 12%, while Seed Enhancement advanced 8% and Beauty Actives rose 6%, highlighting multiple pockets of robust end‑market demand.

Exceptional Charges Mask Underlying Profit Progress

Reported profit before tax dropped to £91m from an adjusted £276m after £150m of exceptional charges. These were driven by a full £45m impairment of the Lamar lipid site and a £29m write‑off of assets under construction, and management cautioned that further impairments are likely as it continues footprint optimization.

Pharma Growth Disappoints Amid Policy-Driven Volatility

Pharma sales rose just 4%, below management’s expectations, as U.S. policy changes weighed on vaccine adjuvant volumes. The Pharma Solutions business, which includes lipids and adjuvants, remains volatile and management has deliberately excluded any breakout growth from its FY2028 base‑case planning.

Industrial Specialties Under Pressure from Volume Declines

Industrial Specialties proved a drag, falling 19% in Q4 against a tough prior-year comparison and ending the year down 2%. A notable factor was lower volumes from Cargill, which now accounts for around 20% of Industrial Specialties sales, highlighting ongoing challenges in more cyclical, lower‑margin end markets.

FX and Inflation Erode Part of Margin Recovery

A roughly one percentage point foreign exchange headwind dampened the visible margin recovery in 2025. On top of that, salary inflation added about £12m and the company flagged an additional £10m depreciation step‑up in 2026, which will weigh on near‑term reported profitability.

Working Capital Volatility and Structural Improvement Plans

Working capital saw an £8m outflow in FY2025, versus a £21m inflow the prior year that was boosted by a one‑off £48m COVID‑related receivable. Management now assumes a more typical £20–30m annual working capital outflow to fund growth, while targeting structural improvements to bring that requirement down over time.

Lamar Lipids Site on Standby Pending Future Demand

The Lamar U.S. lipid facility has been impaired and placed on standby, resulting in a £45m impairment and a £16m onerous contract provision. While Croda has now provided for standby costs and removed future financial exposure, the timing and conditions for resuming full operations will depend on uncertain future breakout demand.

Further Restructuring and Impairments Likely

Management signalled that additional impairments and restructuring charges are probable as it continues to optimize its manufacturing footprint. The transformation is expected to cost about £80m in cash to deliver the £100m of annual savings targeted by 2028, implying more near‑term noise before full benefits flow through.

Guidance and Multi-Year Outlook

Looking ahead, Croda guided FY2026 adjusted operating profit to be in line with market expectations, with organic sales growth of 3–6% and a further margin uplift, though Q1 is expected to be broadly flat after a strong prior-year quarter. By 2028, the company is targeting 3–6% group organic growth, EBITDA margins above 25%, over £100m of annual savings, improved working capital, leverage held at 1–2x EBITDA and a normalized dividend payout of 40–50% of adjusted earnings.

Croda’s call balanced tangible operational progress against clear pockets of risk, giving investors reasons for cautious optimism. Underlying growth, rising adjusted margins and stronger cash generation support the transformation story, yet heavy exceptional charges, pharma and industrial volatility and future restructuring mean the path to its 2028 goals will not be entirely smooth.